Exhibit 107
Calculation of Filing Fee Tables
Registration Statement on Form S-8
LANDOS BIOPHARMA, INC.
| Security Type | Security Class Title |
Fee Calculation Rule |
Amount Registered (1) |
Proposed Maximum Offering Price Per Unit (2) |
Maximum Aggregate Offering Price |
Fee Rate | Amount of Registration Fee | |||||||
| Equity | 2019 EIP Common Stock |
Other | 1,824,900 | $1.68 | $3,065,832 | $92.70 per million | $284.20 | |||||||
| Equity | 2021 ESPP Common Stock |
Other | 402,548 | $1.68 | $676,281 | $92.70 per million | $62.69 | |||||||
| Equity | Inducement Plan Common Stock |
Other | 1,000,000 | $1.68 | $1,680,000 | $92.70 per million | $155.74 | |||||||
| Total Offering Amounts | $5,433,113 | $502.63 | ||||||||||||
| Total Fee Offsets | — | |||||||||||||
| Net Fee Due | $502.63 | |||||||||||||
| (1) | Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Common Stock that become issuable under the 2019 EIP, 2021 ESPP and Inducement Plan set forth herein by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of the Registrant’s Common Stock. |
| (2) | Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) promulgated under the Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price are calculated using the average of the high and low prices of the Registrant’s Common Stock as reported on the Nasdaq Global Market on March 18, 2022. |